Drug discovery of first in class and best in class innovative medicines:Targeted protein degradation drug discovery platform (PROTACs);Oral PROTACs for oncology, delivered 2 PCC into clinical developmentDegrader-antibody conjugate (DAC), degrader as novel payload for next generation of ADCDeuterated drug discovery for oncology, and other indications;Drug discovery using traditional medicinal chemistry approach for oncology and metabolic disease;Delivered a THR-beta agonist for NASHManaging internal medchem team and external chemistry CRO team;Responsibilities included medicinal chemistry, lead optimization, process chemistry, formulation, IP management, business development and external collaboration;Inventor of >30 patents and patent applications;Author/coauthor of >30 peer reviewed publications, including review articles.

Drug discovery, medicinal chemistry. Lead optimization of BMI-1 modulator for cancers, currently in clinical development;Lead identification for antibacterial project, Spinal Muscular Atrophy (SMA) project;Validation for new oncology target;Managing chemistry CRO team in China.

Medicinal chemistry, lead optimization, lead identification. Back up PCC for cannabinoid-1 receptor (CB1) inverse agonist to treat obesity;Lead optimization of SSTR3 antagonist led to PCC for diabetics;Other projects included lead identification for various targets based on HTS hits, patents and literature.

Professor Dale Boger's group: synthetic methodology, medicinal chemistry, Synthesis and SAR studies of FAAH inhibitors;Tandem inverse electron demand Diels-Alder Reaction for poly-ring system.